乌骨藤注射液对Bel-7402细胞增殖及血管生成作用的实验研究
|
摘要
1.目的:
近年来,抗肿瘤血管生成已成为肿瘤治疗的基础和临床研究热点,是最有希望的肿瘤导向治疗靶标,与传统的肿瘤治疗相比,抗肿瘤血管生成治疗的最大特点在于它不但具有良好的特异性,而且克服了药物达到肿瘤组织的不足和肿瘤耐药性等问题。我国的中医药治疗与血管生成相关的病症有着悠久的历史,具有不同于西医的特殊性,并在这些病症的治疗上有极大的优势。因此,研究中药抗肿瘤血管生成,在阐明中医基础理论、临床治疗及中药研究中具有十分重要的意义。乌骨藤,又叫通光藤,为萝藦科牛奶菜属植物,主产于云南、贵州,据记载:该药始载于《滇南本草》,性味苦,微甘、凉,入肺胃膀胱经;具有止咳平喘、消炎镇痛、通乳利尿等功效,用于治疗慢性支气管炎。民间用乌骨藤治疗癌症获得良效,引起广大医药工作者的关注。本试验旨在研究并证明传统中药乌骨藤抗肿瘤活性,从血管内皮生长因子、碱性成纤维细胞生长因子、基质金属蛋白酶-2以及抑癌基因p53等角度探讨乌骨藤的抗肿瘤作用机制。
2.方法:
2.1 MTT法
采用四氮唑盐(MTT)还原法测定不同浓度的乌骨藤注射液的体外对人肝癌细胞Bel-7402细胞增殖的影响,并根据吸光度(OD)值作图得到剂量-效应图谱。
2.2 PI单染法检测细胞凋亡和周期
采用流式细胞术检测不同浓度的乌骨藤注射液对人肝癌细胞Bel-7402凋亡和周期的影响。
2.3 ELISA法
利用ELISA试剂盒检测不同浓度的乌骨藤注射液对人肝癌细胞Bel-7402不同时间段表达VEGF的影响。
2.4免疫细胞化学法
采用细胞免疫化学SP染色法检测不同浓度的乌骨藤注射液作用于人肝癌细胞Bel-7402后bFGF和MMP-2蛋白的阳性表达率。
2.5流式细胞术检测抑癌基因p53蛋白的表达
采用流式细胞术,通过间接荧光标记法测定不同浓度的乌骨藤注射液作用于人肝癌细胞Bel-7402后p53蛋白的表达情况。p53蛋白荧光指数(Fluoresence Index,FI)表示定量的p53蛋白。绿荧光LOG收集的荧光强度峰值数转化成线性刻度,对照管作为阴性表达FI=1。FI计算公式如下:FI=检测管细胞平均荧光强度/对照管细胞平均荧光强度。如FI>1.0为阳性表达,FI≤1.0为阴性表达。
3.结果:
3.1不同浓度的乌骨藤注射液(10mg/ml、20mg/ml、40mg/ml)对人肝癌细胞Bel-7402均有抑制作用,且呈剂量时间依赖,经统计学分析有差异。
3.2人肝癌细胞Bel-7402经不同浓度的乌骨藤注射液(20mg/ml、40mg/ml、80mg/ml)作用后,细胞凋亡率明显上升,且呈剂量依赖,经统计学分析有意义。然而,细胞周期变化不大,未证实细胞被阻滞于特定周期。
3.3利用ELISA试剂盒检测不同浓度的乌骨藤注射液(10mg/ml、20mg/ml、40mg/ml)作用于人肝癌细胞Bel-7402后VEGF的表达情况,随着药物浓度的增加,VEGF表达逐渐减少,且与阴性对照组相比均有统计学差异。
3.4免疫细胞化学的结果显示,不同浓度的乌骨藤注射液(10mg/ml、20mg/ml、40mg/ml)作用于人肝癌细胞Bel-7402后,与阴性对照组相比,bFGF和MMP-2的表达均有所减少,经统计学分析有差异。
3.5流式细胞免疫荧光检测p53蛋白的结果显示,随着药物浓度的增加,荧光强度增加,p53峰总体向右偏移。根据FI计算公式计算出FI值,经不同浓度的乌骨藤注射液作用24h后,p53均阳性表达,且FI值随剂量的增加而增高。
4.结论:
乌骨藤注射液体外具有较强的抗肿瘤作用,一方面乌骨藤注射液可以下调肿瘤细胞VEGF、bFGF、MMP-2的表达,从而阻断了肿瘤的血管生成和转移侵袭,另一方面,乌骨藤注射液可以激活p53基因的表达诱导肿瘤细胞的凋亡,且p53的激活又可以抑制VEGF的表达,进一步阻断了肿瘤血管的生成。乌骨藤注射液可能是通过诱导肿瘤细胞凋亡和阻断肿瘤血管生成与转移侵袭发挥抗肿瘤作用的。
1.Objectives:
Recently, the anti-tumor angiogenesis tumor therapy, which is the most promising treatment of tumor targeted therapy, has become a basic and clinical research hot spots. Compared with the traditional treatment of cancer, the most prominent feature of anti-angiogenesis therapy is that it not only is well specific, but also overcomes the deficient of drug resistance and the difficulty of medicine reaching neoplastic tissue .The history of the treatment of the traditional Chinese medicine on angiogenesis is very long in time . With different specificity of Western medicine it shows a great grace. Therefore, research on anti-angiogenesis therapy in the area of the treatment of cancer by traditional Chinese medicine is very significant in the territories of elucidating the basic theory of traditional Chinese medicine, clinical treatment and research on Chinese medicine.
Glaucescent Fissistigma Root, also known as Marsdenia tenacissima(Roxb.)Wight et Arn, which is bitter, cool and a little sweet,mainly grows in Yunnan and Guizhou province.According to records,it was first recorded in the "Materia Medica polyanthum" . It can stop coughing and gasping ,eliminate inflammation,relieve pain and has the effect of lactogenesis and diuresis.It was used to treat chronic bronchitis. People obtain fine effect in the process of using Glaucescent Fissistigma Root treating cancers. So it draws attention by many Chinese medicine practitioners. This test is to study and prove that traditional Chinese medicine Glaucescent Fissistigma Root can treat tumor.We investigate the mechanism of anti-tumor from the facts of vascular endothelial growth factor , basic fibroblast growth factor, MMP-2 and p53 .
2.Methods:
2.1 MTT method
Apply MTT deoxidized method to survey the rate of Glaucescent Fissistigma Root inhibiting tumor cell in vitro. Hepatoma carcinoma cell strain Bel-7402 is effected by different density of Glaucescent Fissistigma Root.We get dosage-effectiveness atlas by the OD.
2.2 PI single-staining method
Apply flow cytometry to detect cell cycle and apoptosis cell population of Bel-7402 cells effected by different concentrations of Glaucescent Fissistigma Root.
2.3 ELISA method
Apply ELISA Kit to detect the expression of VEGF of Bel-7402 cells in different time effected by different concentrations of Glaucescent Fissistigma Root.
2.4 Immunocytochemical method
Apply Immunocytochemical method to detect the positive expression rate of b-FGF and MMP-2 protein of Bel-7402 cells effected by different concentrations of Glaucescent Fissistigma Root.
2.5 Flow cytometry detect anti-oncogene-p53 proteinum
Apply flow cytometry to survey p53 proteinum transmutation expressed by Bel-7402 cells, through indirect fluorescent labelling method.P53 proteinum Fluoresence Index(FI) express quantitative p53 proteinum. Green fluoresence LOG collect fluorescence intensity peak amplitude number, which convert linearity scale. It take peak amplitude number of contrast control tube as negative expression FI=1. FI calculated formula as follow: FI= mean fluorecence intensity of detector tube cell / mean fluorecence intensity of detector tube cell contrast control tube. For instance FI>1.0 for masculine expression, FI≤1.0 for negative expression.
3.Results:
3.1 Four densities of Glaucescent Fissistigma Root(10,20,40mg/ml) have determinate depressant effect on Bel-7402 cells.And the effection is dose-time-dependent. It is significant through statistics analysising discrepancy(P<0.01).
3.2 A marked increase in the apoptosis rate of human liver cancer cells Bel-7402 by different concentrations of Glaucescent Fissistigma Root(20,40,80mg/ml) appeared. It is significant through statistics analysising discrepancy.However, there is little change in the cell cycle, which did not confirm that cells were arrested at a specific cycle.
3.3 Apply ELISA Kit to detect the expression of VEGF in human liver cancer cell Bel-7402 effected by different concentrations of Glaucescent Fissistigma Root(10,20,40mg/ml). With the increase in drug concentration, VEGF expression gradually reduced.Compared with the negative control group,it is significant.
3.4 The result of immunocytochemistry showed that compared with the negative control group,the expression of bFGF and MMP-2 of Bel-7402 cells effected by different concentrations of Glaucescent Fissistigma Root(10,20,40mg/ml) has been reduced.
3.5 Utilizing flow cytometry immunofluorescence technic detect p53 gene product, along with the accrescence of medicine density, p53 peak offset rightward overall. According to FI formula calculation, it could calculate FI numerical value. The tumor cells are effected by different concentrations of Glaucescent Fissistigma Root(10,20,40mg/ml) for 24 hours, p53 proteinum in them all show masccline expression,and the FI numerical value increase along with the accrescence of dosage.
4.Conclusion:
Glaucescent Fissistigma Root has a strong anti-tumor effects in vitro.It can inhibit VEGF, b-FGF, MMP-2 and other substances in the expression of angiogenesis. The mechanism was probably related to the activation of tumor suppressor gene p53 and inhibition of other angiogenic factors, inhibiting tumor cell and endothelial cell proliferation and inducing apoptosis of tumor cells to block tumor angiogenesis.
近年来,抗肿瘤血管生成已成为肿瘤治疗的基础和临床研究热点,是最有希望的肿瘤导向治疗靶标,与传统的肿瘤治疗相比,抗肿瘤血管生成治疗的最大特点在于它不但具有良好的特异性,而且克服了药物达到肿瘤组织的不足和肿瘤耐药性等问题。我国的中医药治疗与血管生成相关的病症有着悠久的历史,具有不同于西医的特殊性,并在这些病症的治疗上有极大的优势。因此,研究中药抗肿瘤血管生成,在阐明中医基础理论、临床治疗及中药研究中具有十分重要的意义。乌骨藤,又叫通光藤,为萝藦科牛奶菜属植物,主产于云南、贵州,据记载:该药始载于《滇南本草》,性味苦,微甘、凉,入肺胃膀胱经;具有止咳平喘、消炎镇痛、通乳利尿等功效,用于治疗慢性支气管炎。民间用乌骨藤治疗癌症获得良效,引起广大医药工作者的关注。本试验旨在研究并证明传统中药乌骨藤抗肿瘤活性,从血管内皮生长因子、碱性成纤维细胞生长因子、基质金属蛋白酶-2以及抑癌基因p53等角度探讨乌骨藤的抗肿瘤作用机制。
2.方法:
2.1 MTT法
采用四氮唑盐(MTT)还原法测定不同浓度的乌骨藤注射液的体外对人肝癌细胞Bel-7402细胞增殖的影响,并根据吸光度(OD)值作图得到剂量-效应图谱。
2.2 PI单染法检测细胞凋亡和周期
采用流式细胞术检测不同浓度的乌骨藤注射液对人肝癌细胞Bel-7402凋亡和周期的影响。
2.3 ELISA法
利用ELISA试剂盒检测不同浓度的乌骨藤注射液对人肝癌细胞Bel-7402不同时间段表达VEGF的影响。
2.4免疫细胞化学法
采用细胞免疫化学SP染色法检测不同浓度的乌骨藤注射液作用于人肝癌细胞Bel-7402后bFGF和MMP-2蛋白的阳性表达率。
2.5流式细胞术检测抑癌基因p53蛋白的表达
采用流式细胞术,通过间接荧光标记法测定不同浓度的乌骨藤注射液作用于人肝癌细胞Bel-7402后p53蛋白的表达情况。p53蛋白荧光指数(Fluoresence Index,FI)表示定量的p53蛋白。绿荧光LOG收集的荧光强度峰值数转化成线性刻度,对照管作为阴性表达FI=1。FI计算公式如下:FI=检测管细胞平均荧光强度/对照管细胞平均荧光强度。如FI>1.0为阳性表达,FI≤1.0为阴性表达。
3.结果:
3.1不同浓度的乌骨藤注射液(10mg/ml、20mg/ml、40mg/ml)对人肝癌细胞Bel-7402均有抑制作用,且呈剂量时间依赖,经统计学分析有差异。
3.2人肝癌细胞Bel-7402经不同浓度的乌骨藤注射液(20mg/ml、40mg/ml、80mg/ml)作用后,细胞凋亡率明显上升,且呈剂量依赖,经统计学分析有意义。然而,细胞周期变化不大,未证实细胞被阻滞于特定周期。
3.3利用ELISA试剂盒检测不同浓度的乌骨藤注射液(10mg/ml、20mg/ml、40mg/ml)作用于人肝癌细胞Bel-7402后VEGF的表达情况,随着药物浓度的增加,VEGF表达逐渐减少,且与阴性对照组相比均有统计学差异。
3.4免疫细胞化学的结果显示,不同浓度的乌骨藤注射液(10mg/ml、20mg/ml、40mg/ml)作用于人肝癌细胞Bel-7402后,与阴性对照组相比,bFGF和MMP-2的表达均有所减少,经统计学分析有差异。
3.5流式细胞免疫荧光检测p53蛋白的结果显示,随着药物浓度的增加,荧光强度增加,p53峰总体向右偏移。根据FI计算公式计算出FI值,经不同浓度的乌骨藤注射液作用24h后,p53均阳性表达,且FI值随剂量的增加而增高。
4.结论:
乌骨藤注射液体外具有较强的抗肿瘤作用,一方面乌骨藤注射液可以下调肿瘤细胞VEGF、bFGF、MMP-2的表达,从而阻断了肿瘤的血管生成和转移侵袭,另一方面,乌骨藤注射液可以激活p53基因的表达诱导肿瘤细胞的凋亡,且p53的激活又可以抑制VEGF的表达,进一步阻断了肿瘤血管的生成。乌骨藤注射液可能是通过诱导肿瘤细胞凋亡和阻断肿瘤血管生成与转移侵袭发挥抗肿瘤作用的。
1.Objectives:
Recently, the anti-tumor angiogenesis tumor therapy, which is the most promising treatment of tumor targeted therapy, has become a basic and clinical research hot spots. Compared with the traditional treatment of cancer, the most prominent feature of anti-angiogenesis therapy is that it not only is well specific, but also overcomes the deficient of drug resistance and the difficulty of medicine reaching neoplastic tissue .The history of the treatment of the traditional Chinese medicine on angiogenesis is very long in time . With different specificity of Western medicine it shows a great grace. Therefore, research on anti-angiogenesis therapy in the area of the treatment of cancer by traditional Chinese medicine is very significant in the territories of elucidating the basic theory of traditional Chinese medicine, clinical treatment and research on Chinese medicine.
Glaucescent Fissistigma Root, also known as Marsdenia tenacissima(Roxb.)Wight et Arn, which is bitter, cool and a little sweet,mainly grows in Yunnan and Guizhou province.According to records,it was first recorded in the "Materia Medica polyanthum" . It can stop coughing and gasping ,eliminate inflammation,relieve pain and has the effect of lactogenesis and diuresis.It was used to treat chronic bronchitis. People obtain fine effect in the process of using Glaucescent Fissistigma Root treating cancers. So it draws attention by many Chinese medicine practitioners. This test is to study and prove that traditional Chinese medicine Glaucescent Fissistigma Root can treat tumor.We investigate the mechanism of anti-tumor from the facts of vascular endothelial growth factor , basic fibroblast growth factor, MMP-2 and p53 .
2.Methods:
2.1 MTT method
Apply MTT deoxidized method to survey the rate of Glaucescent Fissistigma Root inhibiting tumor cell in vitro. Hepatoma carcinoma cell strain Bel-7402 is effected by different density of Glaucescent Fissistigma Root.We get dosage-effectiveness atlas by the OD.
2.2 PI single-staining method
Apply flow cytometry to detect cell cycle and apoptosis cell population of Bel-7402 cells effected by different concentrations of Glaucescent Fissistigma Root.
2.3 ELISA method
Apply ELISA Kit to detect the expression of VEGF of Bel-7402 cells in different time effected by different concentrations of Glaucescent Fissistigma Root.
2.4 Immunocytochemical method
Apply Immunocytochemical method to detect the positive expression rate of b-FGF and MMP-2 protein of Bel-7402 cells effected by different concentrations of Glaucescent Fissistigma Root.
2.5 Flow cytometry detect anti-oncogene-p53 proteinum
Apply flow cytometry to survey p53 proteinum transmutation expressed by Bel-7402 cells, through indirect fluorescent labelling method.P53 proteinum Fluoresence Index(FI) express quantitative p53 proteinum. Green fluoresence LOG collect fluorescence intensity peak amplitude number, which convert linearity scale. It take peak amplitude number of contrast control tube as negative expression FI=1. FI calculated formula as follow: FI= mean fluorecence intensity of detector tube cell / mean fluorecence intensity of detector tube cell contrast control tube. For instance FI>1.0 for masculine expression, FI≤1.0 for negative expression.
3.Results:
3.1 Four densities of Glaucescent Fissistigma Root(10,20,40mg/ml) have determinate depressant effect on Bel-7402 cells.And the effection is dose-time-dependent. It is significant through statistics analysising discrepancy(P<0.01).
3.2 A marked increase in the apoptosis rate of human liver cancer cells Bel-7402 by different concentrations of Glaucescent Fissistigma Root(20,40,80mg/ml) appeared. It is significant through statistics analysising discrepancy.However, there is little change in the cell cycle, which did not confirm that cells were arrested at a specific cycle.
3.3 Apply ELISA Kit to detect the expression of VEGF in human liver cancer cell Bel-7402 effected by different concentrations of Glaucescent Fissistigma Root(10,20,40mg/ml). With the increase in drug concentration, VEGF expression gradually reduced.Compared with the negative control group,it is significant.
3.4 The result of immunocytochemistry showed that compared with the negative control group,the expression of bFGF and MMP-2 of Bel-7402 cells effected by different concentrations of Glaucescent Fissistigma Root(10,20,40mg/ml) has been reduced.
3.5 Utilizing flow cytometry immunofluorescence technic detect p53 gene product, along with the accrescence of medicine density, p53 peak offset rightward overall. According to FI formula calculation, it could calculate FI numerical value. The tumor cells are effected by different concentrations of Glaucescent Fissistigma Root(10,20,40mg/ml) for 24 hours, p53 proteinum in them all show masccline expression,and the FI numerical value increase along with the accrescence of dosage.
4.Conclusion:
Glaucescent Fissistigma Root has a strong anti-tumor effects in vitro.It can inhibit VEGF, b-FGF, MMP-2 and other substances in the expression of angiogenesis. The mechanism was probably related to the activation of tumor suppressor gene p53 and inhibition of other angiogenic factors, inhibiting tumor cell and endothelial cell proliferation and inducing apoptosis of tumor cells to block tumor angiogenesis.
引文
[1]Liotta LA,Tumor invasion and metastasis role of the extracellular matrix :Rhoads memorial award lecture[J] . Cancer Res ,1986 ,46 (1) :1-7.
[2]Cao Y, O' Reilly MS, Marshall B, et al. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest, 1998,101(5):1055-1063.
[3] Baillie C T , Winslet M C , Bradley N J . Tumor Vasculatur-apotential therapeutic target [J] . Br J Cancer , 1995 ,27 (3) :257.
[4]Hanahan D,Folkman J.Patterns and emerging mechanisms of the anginogenic switch during tumorigenesis[J].Cell,1996,86:353-364.
[5]Tischer E, Mitchell R, Hartman T, et al The human gene for Vascular Endothelial Growth Factor,Multiple protein forms are encoded through alternative exon splicing. J Biol Chem,1991,266:11947～11954.
[6]Neufeld G,Cohen T,Gengrinovitch S, et al Vascular endothelial growth factor(VEGF) and its receptors. JFASEB,1999,13:9～22.
[7]Zeng ZS,Cohen AM,Guillem JG..Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9(MMP-2 and MMP-9) during human colorectal tumorigenesis.Carcinogenesis,1999,20(5):749-755.
[8]方蓉. MTT比色法的条件探讨.临床检验杂志, 2003, 21(1);34-35.
[9] Morkve, OD Laerum. Flow cytometric measurement of p53 protein expression and DNA content in paraffin-embedded tissue from bronchial carcinoma. Cytometry,1991,12(5): 438-444.
[10]Folkman,J.Tumor angiogenesis:therapeutic implication .New Engl.J.Med.1971,285 (21):1182-1186.
[11]Folkman,J.What is the evidence that tumors are angiogenesis dependent?J.Natl.Cancer Inst.1990,80:4-6.
[12]Folkman,J.Angiogenesis inhibitors generated by tumors.Breast Cancer Res. 1995,36:181-192.
[13]Chiaryg V,Ruggiero M,Magnelli L. Angiogenesis and unique nature of tumor matrix.Mol.Biotechnol.2002,62(20):85.
[14]Mahadevan V,Hart IR.Metastasis and angiogenesis.Acta.Oncol.1990,29(2):97.
[15]Liekens S,De Clercq E,Neyts J. Angiogenesis:regulators and clinical applications. Biochem.Pharmacol.2001,61:253-270.
[16]Klohs WD,Hamby JM.Antiangiogenic ageDnts.Curr Opin.Biotechnol.1999,10:544 -549.
[17]张明智,何振,吴广银,等.消癌平对EC-9706食管癌细胞的作用及机制实验研究[J].时珍国医国药,2008,19(5):1182-1183.
[18]李东,欧阳建,李翠萍,等.消癌平注射液对白血病细胞NB4作用的初步研究[J].中国生化药物杂志,2007,28(4):247-250.
[19]李东,欧阳建,李翠萍,等.通关藤诱导白血病细胞U937,HL60细胞凋亡的实验研究[J].中国生化药物杂志,2008,29(1):33-37.
[20]Wey JS,Fan F, Gray M J,et al.Vascular endothelial growth factor receptor-1 promotes migration and invasionin pancreatic carcinoma cell lines. Cancer,2005, 104(2):427.
[21]Shibuya M.Stucture and dual function of vascular endothelial growth factor receptor-1(flt-1).Int J Bio chem.Cell Biol,2001,33:4409.
[22]Shibuya M. Stucture and dual function of VEGF/VEGF-receptor system invoved inangiogenesis .Cell Struct Funct,2001,26:25.
[23]Skobe M,Hawighorst T,Jackson DG ,et al.Induction of tumor lymphangiopnesis by VEGF-C promotes breast cancer metastasis.Nature Med,2001,7(2):192.
[24]Dias S,Shmelkov SV,Lam G,et al.VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of bcl-2 expression and apoptosis inhibition. Blood,2002,99(7):2532-2540.
[25]Damico FM.Angiogenesis and retinal diseases[J]. Arq Bras Oftalmol, 2007,70(3):547-53.
[26]Patry V,Bugler B, Maret A, et al. Endogenous basic fibroblast growth factor isoforms involved in different intracellular protein complexes[J].Biochem J,1997,326(Pt 1):259-264.
[27]Majors A,Ehrhart L A.Basic fibroblast growth factor in the extracellular matrix suppresses collagen synthesis and type III procollagen mRNA levels in arterial smooth muscle cell cultures[J]. Arterioscler Thromb,1993,13(5):680-686.
[28]王楠,徐永华.佛波脂PMA促进碱性成纤维细胞生成长因子(bFGF)释放及机理的研究[J].实验生物学报,1998,31(1):41-48.
[29]Fukata S,Inoue K,Kamada M,et al.Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organspecificmetastasisofrenal cell caicinoma Cancer,2005,103:931-942.
[30]VU TH,Shipley JM,Bergers G,et al.Gelatinases is a key regulator of growth plate angiogenesis and apoptosis of hyper-trophic chondrocytes[J].Cell,1998,93(3):411-422.
[31] Qun Lu,Wang Hong. Bcl2 enhances c-Myc-mediated MMP-2 expression of vascular smooth muscle cells. Cellular Signalling,2009,21:1054-1059.
[32]Ravi R,Mookerjee B, Bhujwalla Z N,et al.Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α.Genes Dev,2000,14:34-44.
[33]Schmid T,Zhou J,Brune B.HIF-1 and p53:conmunication of transcription factors under hypoxia.J Cell Mol Med,2004,8(4):423-431.
[34]Michael Bouvet, Lee M. Ellis, Masahiko Nishizaki,et al.Adenovirus-mediated Wild-Type p53 Gene Transfer Down-Regulates Vascular Endothelial Growth Factor Expression and Inhibits Angiogenesis in Human Colon Cancer. Cancer Research,1998,58:2288-2292.
[35] Timo Gaiser,Maria R.Becker,Jochen Meyer,et al.p53-mediated inhibition of angiogenesis in diffuse low-grade astrocytomas. Neurochemistry International , 2009, 54:458-463.
[36]施明,王福生,刘明旭,等.BEL-7402、HLE及HuH-7细胞p53基因突变检测.世界华人消化杂志,2001,9(11):1330-1332.
[37]Wang S,Lai Y H,Tain B,et al.Two new C21 steroidal glycosides from Marsdenia tenacissima(ROXB) WIGHT et ARN[J].Chem Pharm Bull,2006,54(5):696-698.
[38]刑旺兴,陈斌.通光藤中两个新C21甾体苷类成分[J].药学学报,2004,39(4):272-275.
[1]刑旺兴,程荣珍,陈斌,等.乌骨藤常见混用品种辨析[J].现代中药研究与实践,2004,18(1):33-36.
[2]江苏新医学院.中药大辞典(下册)[M].上海:上海科学技术出版社,1999.1976.
[3]中国药科大学.中药辞海(第2卷)[M].北京:中国医药科技出版社,1996.2360-2361.
[4]刘玉芬,孙凤英,王玲.乌骨藤化学成分研究[J].中成药,1998,20(9):35
[5]张明智,何振,吴广银,等.消癌平对EC-9706食管癌细胞的作用及机制实验研究[J].时珍国医国药,2008,19(5):1182-1183.
[6]李东,欧阳建,李翠萍,等.消癌平注射液对白血病细胞NB4作用的初步研究[J].中国生化药物杂志,2007,28(4):247-250.
[7]李东,欧阳建,李翠萍,等.通关藤诱导白血病细胞U937,HL60细胞凋亡的实验研究[J].中国生化药物杂志,2008,29(1):33-37.
[8]孙珏,沈建华,朱美华,等.消癌平对人肝癌细胞治疗作用的实验研究[J].上海中医药大学学报,2006,14(2):41-43.
[9]李茂全,沈建华,青彬,等.消癌平对SGC-7901胃癌细胞的作用及机制的实验研究[J].介入放射学杂志,2001,10(4):228-231.
[10]朱萱萱,赵路华,严士海,等.乌骨藤提取物体外对人肠癌细胞增殖实验研究[J].内蒙古中医药,2008,(3):46-48.
[11]周丹,韩大庆,刘伟,等.消癌平片抗肿瘤作用研究[J].吉林中医药,2002,22(1): 57-58.
[12]朱萱萱,赵路华,顾和亚,等.乌骨藤提取物对小鼠移植性实体瘤H22和S180的抑制作用[J].药物研究,2008,17(11):7-8.
[13]赵晓兴,李格来.消癌平治疗晚期恶性肿瘤42例疗效及毒性临床观察[J].河南肿瘤学杂志,1993,6(3):215-216
[14]王志良,攀青霞,范魁生.消癌平临床疗效观察[J].河南医科大学学报,1994,29(1):79-80.
[15]胡赤丁.消癌平治疗晚期恶性肿瘤33例[J]医药导报,2001,20(10):62.
[16]梁素美,文欣轩,王静.消癌平注射液治疗43例晚期消化道系统肿瘤的临床观察[J].中国临床医药研究杂志,2003,93:9234-9235.
[17]温建珍,郝青,杨玲.消癌平注射液治疗老年晚期消化道肿瘤57例[J].中国民间疗法,2003,11(6):48.
[18]袁秀英,范忠泽,黄秀英.消癌平注射液治疗14例晚期胃癌的临床观察[J].上海医药,1996,(6 ):12-13.
[19]王如美,赵素斌,李宏军,等.消癌平注射液治疗晚期胃癌14例临床观察[J].邯郸医学高等专科学校学报,2005,18(5):416-417.
[20]孙珏,沈建华,朱美华,等.中药消癌平针剂经肝动脉介入治疗转移性肝癌的临床研究[J].上海中医药杂志,2000,31(1):14-17.
[21]卢秋红,邓力.消癌平肝动脉灌注配合肝动脉栓塞化疗治疗肝癌的临床观察[J].现代中西医结合杂志,2004,13(20):2690-2691.
[22]王文荣,崔生达,曾黎明.中药消癌平配合超声引导经皮射频治疗中晚期肝癌的临床观察[J].中国中西医结合杂志,2003,23(1):19-21.
[23]赵素斌,王如美,李守霞.消癌平治疗原发性肝癌的临床疗效[J].邯郸医学高等专科学校学报,2005,18(5):415-416.
[24]黄振倩,谭获,王春燕,等.消癌平注射液联合化疗治疗中晚期肺癌的临床研究[J].临床肿瘤学杂志,2007,12(2):97-99.
[25]杨眠,吴静,李永强,等.消癌平注射液联合放疗治疗晚期非小细胞肺癌30例[J].中医研究,2000,13(1):39-41.
[26]裴毅,魏淑青,杨永明,等.消癌平一生长抑素类似物治疗难治性卵巢癌的初步临床观察[J].肿瘤研究与临床,2006,18(7):469-471.
[1]曾小莉,涂植光.人参总皂苷诱导肝癌细胞分化初探[J]。肿瘤防治研究,2000,27(3):188-190.
[2]曾小莉,涂植光.人参皂甙rh2对人肝癌细胞SMMC-7721的诱导分化作用[J]。癌症, 2004,23(8):879-884.
[3]曾小莉,涂植光.端粒酶在人参皂甙Rh2诱导肝癌细胞分化中的作用[J]。癌症,2004,23(12):1655-1659.
[4]袁淑兰.丹参酮对人肝癌细胞某些表型的逆转作用[J].肿瘤,1997, 17(5):268-270.
[5]梁勇,羊裔明,袁淑兰,等.丹参酮ⅡA诱导急性早幼粒细胞白血病分化及其分子机制[J].中华血液杂志,2000 ,21(1):23-26.
[6]吴俣,羊裔明,孟文彤,等.丹参酮对K562细胞株的诱导分化[J].华西医科大学学报,2002,33(1): 80-83.
[7]张燕军,夏天,赵建斌.苦参碱对SMMC一7721细胞系的诱导分化作用[J].第四军医大学学报,1998,19 (3):340-342.
[8]黄建,张鸣杰等.苦参碱抑制大肠癌HT-29细胞环氧化酶-2表达的研究[J].中国中西医结合杂志,2005,25(3):240-243.
[9]何於娟,蒋纪恺,欧一衡,等.苦参碱对K562细胞早期原癌基因表达的影响[J].癌症,2002,21(4):369-372.
[10]黄炜黄济群张东方,等. 18β-甘草次酸和甘草酸对人肝癌细胞增殖的抑制和诱导分化作用[J].中国中医药科技,2002,9(2):92-93.
[11]黄炜黄济群张东方,等.全反式维甲酸、18β-甘草次酸和甘草酸诱导人肝癌细胞分化和凋亡的研究[J].中西医结合肝病杂志,2003,13(3):148-150.
[12]王志红,林菁.盐酸小檗碱对HL-60细胞的诱导分化及其作用机制[J].中国药科大学,2006 ,37(2):165-168.
[13]王泽剑,吴英理,林琦,等.人参炔醇对HL-60细胞体外诱导分化作用的研究[J].中草药, 2003, 34(8):736- 738.
[14]解方为,欧阳学农,蒋明德.红景天甙对人肝癌细胞的诱导分化作用[J],西南国防医药,2005,15 (6):613-615.
[15]解方为,欧阳学农,蒋明德.红景天甙对人肝癌细胞c-myc表达的逆转作用[J],西南国防医药,2006,16(2):130-131.
[16] Lei Liu, Hudgins WR, Shack S, et al. Cinnamic acid:A natural product with potential use in cancer intervention [J]. Int J Cancer, 1995, 629 (3):345- 350.
[17]钱海鑫刘俊卯.桂皮酸体外诱导人肝癌细胞分化[J],江苏医药杂志,2001,27(1):17-19.
[18]朱文渊,董济群,梁雪清.桂皮酸对HL-60细胞诱导分化[J].肿瘤防治研究, 2003, 30(2): 92-94.
[19]黄炜,黄济群,朱文渊,等.桂皮酸诱导白血病肝癌肺癌细胞的分化和抗肺癌细胞侵袭作用[J].中山医科大学学报,2002 ,23 (1) :40-43.
[20]葛林阜,董政军,姜国胜,等.淫羊藿甙对急性早幼粒白血病细胞端粒酶活性的影响[J].中国肿瘤生物治疗杂志,2002 ,9 (1) :36-38.
[21]葛林阜,董政军,姜国胜,等.淫羊藿甙对耐药与非耐药HL-60细胞增殖分化的作用[J].中华实用医学,2001 ,3 (18):9-11.
[22]张玲,王芸,毛海婷,等.淫羊藿甙抑制肿瘤细胞端粒酶活性及其调节机制的研究[J].中国免疫学杂志,2002 ,18 (3):191-196.
[23]王莎莉,王亚平,戴勤,等.当归多糖对人粒单系祖细胞和粒系白血病细胞株增殖分化的实验研究[J].重庆医科大学学报,2003,28(3):257-260.
[24]郑敏,王亚平.当归多糖对K562细胞增殖抑制与诱导分化的实验研究[J],中国中西医结合杂志,2002,22(1):54-57.
[25]梁永红,侯华新,黎丹戎,等.板蓝根二酮B体外抗癌活性研究[J],中草药,2000,31(7):531-533.
[26]侯华新,秦箐,黎丹戎,等.板蓝根高级不饱和脂肪组酸的体外抗人肝癌BEL-7402细胞活性[J],中国临床药学杂志,2002,11(1):16-19.
[27]李祺福,欧阳高亮,刘庆榕,等.中国鲎鲎素诱导人肝癌SMMC-7721细胞分化的观察[J],癌症,2002,21(5):480-483.
[2]Cao Y, O' Reilly MS, Marshall B, et al. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest, 1998,101(5):1055-1063.
[3] Baillie C T , Winslet M C , Bradley N J . Tumor Vasculatur-apotential therapeutic target [J] . Br J Cancer , 1995 ,27 (3) :257.
[4]Hanahan D,Folkman J.Patterns and emerging mechanisms of the anginogenic switch during tumorigenesis[J].Cell,1996,86:353-364.
[5]Tischer E, Mitchell R, Hartman T, et al The human gene for Vascular Endothelial Growth Factor,Multiple protein forms are encoded through alternative exon splicing. J Biol Chem,1991,266:11947～11954.
[6]Neufeld G,Cohen T,Gengrinovitch S, et al Vascular endothelial growth factor(VEGF) and its receptors. JFASEB,1999,13:9～22.
[7]Zeng ZS,Cohen AM,Guillem JG..Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9(MMP-2 and MMP-9) during human colorectal tumorigenesis.Carcinogenesis,1999,20(5):749-755.
[8]方蓉. MTT比色法的条件探讨.临床检验杂志, 2003, 21(1);34-35.
[9] Morkve, OD Laerum. Flow cytometric measurement of p53 protein expression and DNA content in paraffin-embedded tissue from bronchial carcinoma. Cytometry,1991,12(5): 438-444.
[10]Folkman,J.Tumor angiogenesis:therapeutic implication .New Engl.J.Med.1971,285 (21):1182-1186.
[11]Folkman,J.What is the evidence that tumors are angiogenesis dependent?J.Natl.Cancer Inst.1990,80:4-6.
[12]Folkman,J.Angiogenesis inhibitors generated by tumors.Breast Cancer Res. 1995,36:181-192.
[13]Chiaryg V,Ruggiero M,Magnelli L. Angiogenesis and unique nature of tumor matrix.Mol.Biotechnol.2002,62(20):85.
[14]Mahadevan V,Hart IR.Metastasis and angiogenesis.Acta.Oncol.1990,29(2):97.
[15]Liekens S,De Clercq E,Neyts J. Angiogenesis:regulators and clinical applications. Biochem.Pharmacol.2001,61:253-270.
[16]Klohs WD,Hamby JM.Antiangiogenic ageDnts.Curr Opin.Biotechnol.1999,10:544 -549.
[17]张明智,何振,吴广银,等.消癌平对EC-9706食管癌细胞的作用及机制实验研究[J].时珍国医国药,2008,19(5):1182-1183.
[18]李东,欧阳建,李翠萍,等.消癌平注射液对白血病细胞NB4作用的初步研究[J].中国生化药物杂志,2007,28(4):247-250.
[19]李东,欧阳建,李翠萍,等.通关藤诱导白血病细胞U937,HL60细胞凋亡的实验研究[J].中国生化药物杂志,2008,29(1):33-37.
[20]Wey JS,Fan F, Gray M J,et al.Vascular endothelial growth factor receptor-1 promotes migration and invasionin pancreatic carcinoma cell lines. Cancer,2005, 104(2):427.
[21]Shibuya M.Stucture and dual function of vascular endothelial growth factor receptor-1(flt-1).Int J Bio chem.Cell Biol,2001,33:4409.
[22]Shibuya M. Stucture and dual function of VEGF/VEGF-receptor system invoved inangiogenesis .Cell Struct Funct,2001,26:25.
[23]Skobe M,Hawighorst T,Jackson DG ,et al.Induction of tumor lymphangiopnesis by VEGF-C promotes breast cancer metastasis.Nature Med,2001,7(2):192.
[24]Dias S,Shmelkov SV,Lam G,et al.VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of bcl-2 expression and apoptosis inhibition. Blood,2002,99(7):2532-2540.
[25]Damico FM.Angiogenesis and retinal diseases[J]. Arq Bras Oftalmol, 2007,70(3):547-53.
[26]Patry V,Bugler B, Maret A, et al. Endogenous basic fibroblast growth factor isoforms involved in different intracellular protein complexes[J].Biochem J,1997,326(Pt 1):259-264.
[27]Majors A,Ehrhart L A.Basic fibroblast growth factor in the extracellular matrix suppresses collagen synthesis and type III procollagen mRNA levels in arterial smooth muscle cell cultures[J]. Arterioscler Thromb,1993,13(5):680-686.
[28]王楠,徐永华.佛波脂PMA促进碱性成纤维细胞生成长因子(bFGF)释放及机理的研究[J].实验生物学报,1998,31(1):41-48.
[29]Fukata S,Inoue K,Kamada M,et al.Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organspecificmetastasisofrenal cell caicinoma Cancer,2005,103:931-942.
[30]VU TH,Shipley JM,Bergers G,et al.Gelatinases is a key regulator of growth plate angiogenesis and apoptosis of hyper-trophic chondrocytes[J].Cell,1998,93(3):411-422.
[31] Qun Lu,Wang Hong. Bcl2 enhances c-Myc-mediated MMP-2 expression of vascular smooth muscle cells. Cellular Signalling,2009,21:1054-1059.
[32]Ravi R,Mookerjee B, Bhujwalla Z N,et al.Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α.Genes Dev,2000,14:34-44.
[33]Schmid T,Zhou J,Brune B.HIF-1 and p53:conmunication of transcription factors under hypoxia.J Cell Mol Med,2004,8(4):423-431.
[34]Michael Bouvet, Lee M. Ellis, Masahiko Nishizaki,et al.Adenovirus-mediated Wild-Type p53 Gene Transfer Down-Regulates Vascular Endothelial Growth Factor Expression and Inhibits Angiogenesis in Human Colon Cancer. Cancer Research,1998,58:2288-2292.
[35] Timo Gaiser,Maria R.Becker,Jochen Meyer,et al.p53-mediated inhibition of angiogenesis in diffuse low-grade astrocytomas. Neurochemistry International , 2009, 54:458-463.
[36]施明,王福生,刘明旭,等.BEL-7402、HLE及HuH-7细胞p53基因突变检测.世界华人消化杂志,2001,9(11):1330-1332.
[37]Wang S,Lai Y H,Tain B,et al.Two new C21 steroidal glycosides from Marsdenia tenacissima(ROXB) WIGHT et ARN[J].Chem Pharm Bull,2006,54(5):696-698.
[38]刑旺兴,陈斌.通光藤中两个新C21甾体苷类成分[J].药学学报,2004,39(4):272-275.
[1]刑旺兴,程荣珍,陈斌,等.乌骨藤常见混用品种辨析[J].现代中药研究与实践,2004,18(1):33-36.
[2]江苏新医学院.中药大辞典(下册)[M].上海:上海科学技术出版社,1999.1976.
[3]中国药科大学.中药辞海(第2卷)[M].北京:中国医药科技出版社,1996.2360-2361.
[4]刘玉芬,孙凤英,王玲.乌骨藤化学成分研究[J].中成药,1998,20(9):35
[5]张明智,何振,吴广银,等.消癌平对EC-9706食管癌细胞的作用及机制实验研究[J].时珍国医国药,2008,19(5):1182-1183.
[6]李东,欧阳建,李翠萍,等.消癌平注射液对白血病细胞NB4作用的初步研究[J].中国生化药物杂志,2007,28(4):247-250.
[7]李东,欧阳建,李翠萍,等.通关藤诱导白血病细胞U937,HL60细胞凋亡的实验研究[J].中国生化药物杂志,2008,29(1):33-37.
[8]孙珏,沈建华,朱美华,等.消癌平对人肝癌细胞治疗作用的实验研究[J].上海中医药大学学报,2006,14(2):41-43.
[9]李茂全,沈建华,青彬,等.消癌平对SGC-7901胃癌细胞的作用及机制的实验研究[J].介入放射学杂志,2001,10(4):228-231.
[10]朱萱萱,赵路华,严士海,等.乌骨藤提取物体外对人肠癌细胞增殖实验研究[J].内蒙古中医药,2008,(3):46-48.
[11]周丹,韩大庆,刘伟,等.消癌平片抗肿瘤作用研究[J].吉林中医药,2002,22(1): 57-58.
[12]朱萱萱,赵路华,顾和亚,等.乌骨藤提取物对小鼠移植性实体瘤H22和S180的抑制作用[J].药物研究,2008,17(11):7-8.
[13]赵晓兴,李格来.消癌平治疗晚期恶性肿瘤42例疗效及毒性临床观察[J].河南肿瘤学杂志,1993,6(3):215-216
[14]王志良,攀青霞,范魁生.消癌平临床疗效观察[J].河南医科大学学报,1994,29(1):79-80.
[15]胡赤丁.消癌平治疗晚期恶性肿瘤33例[J]医药导报,2001,20(10):62.
[16]梁素美,文欣轩,王静.消癌平注射液治疗43例晚期消化道系统肿瘤的临床观察[J].中国临床医药研究杂志,2003,93:9234-9235.
[17]温建珍,郝青,杨玲.消癌平注射液治疗老年晚期消化道肿瘤57例[J].中国民间疗法,2003,11(6):48.
[18]袁秀英,范忠泽,黄秀英.消癌平注射液治疗14例晚期胃癌的临床观察[J].上海医药,1996,(6 ):12-13.
[19]王如美,赵素斌,李宏军,等.消癌平注射液治疗晚期胃癌14例临床观察[J].邯郸医学高等专科学校学报,2005,18(5):416-417.
[20]孙珏,沈建华,朱美华,等.中药消癌平针剂经肝动脉介入治疗转移性肝癌的临床研究[J].上海中医药杂志,2000,31(1):14-17.
[21]卢秋红,邓力.消癌平肝动脉灌注配合肝动脉栓塞化疗治疗肝癌的临床观察[J].现代中西医结合杂志,2004,13(20):2690-2691.
[22]王文荣,崔生达,曾黎明.中药消癌平配合超声引导经皮射频治疗中晚期肝癌的临床观察[J].中国中西医结合杂志,2003,23(1):19-21.
[23]赵素斌,王如美,李守霞.消癌平治疗原发性肝癌的临床疗效[J].邯郸医学高等专科学校学报,2005,18(5):415-416.
[24]黄振倩,谭获,王春燕,等.消癌平注射液联合化疗治疗中晚期肺癌的临床研究[J].临床肿瘤学杂志,2007,12(2):97-99.
[25]杨眠,吴静,李永强,等.消癌平注射液联合放疗治疗晚期非小细胞肺癌30例[J].中医研究,2000,13(1):39-41.
[26]裴毅,魏淑青,杨永明,等.消癌平一生长抑素类似物治疗难治性卵巢癌的初步临床观察[J].肿瘤研究与临床,2006,18(7):469-471.
[1]曾小莉,涂植光.人参总皂苷诱导肝癌细胞分化初探[J]。肿瘤防治研究,2000,27(3):188-190.
[2]曾小莉,涂植光.人参皂甙rh2对人肝癌细胞SMMC-7721的诱导分化作用[J]。癌症, 2004,23(8):879-884.
[3]曾小莉,涂植光.端粒酶在人参皂甙Rh2诱导肝癌细胞分化中的作用[J]。癌症,2004,23(12):1655-1659.
[4]袁淑兰.丹参酮对人肝癌细胞某些表型的逆转作用[J].肿瘤,1997, 17(5):268-270.
[5]梁勇,羊裔明,袁淑兰,等.丹参酮ⅡA诱导急性早幼粒细胞白血病分化及其分子机制[J].中华血液杂志,2000 ,21(1):23-26.
[6]吴俣,羊裔明,孟文彤,等.丹参酮对K562细胞株的诱导分化[J].华西医科大学学报,2002,33(1): 80-83.
[7]张燕军,夏天,赵建斌.苦参碱对SMMC一7721细胞系的诱导分化作用[J].第四军医大学学报,1998,19 (3):340-342.
[8]黄建,张鸣杰等.苦参碱抑制大肠癌HT-29细胞环氧化酶-2表达的研究[J].中国中西医结合杂志,2005,25(3):240-243.
[9]何於娟,蒋纪恺,欧一衡,等.苦参碱对K562细胞早期原癌基因表达的影响[J].癌症,2002,21(4):369-372.
[10]黄炜黄济群张东方,等. 18β-甘草次酸和甘草酸对人肝癌细胞增殖的抑制和诱导分化作用[J].中国中医药科技,2002,9(2):92-93.
[11]黄炜黄济群张东方,等.全反式维甲酸、18β-甘草次酸和甘草酸诱导人肝癌细胞分化和凋亡的研究[J].中西医结合肝病杂志,2003,13(3):148-150.
[12]王志红,林菁.盐酸小檗碱对HL-60细胞的诱导分化及其作用机制[J].中国药科大学,2006 ,37(2):165-168.
[13]王泽剑,吴英理,林琦,等.人参炔醇对HL-60细胞体外诱导分化作用的研究[J].中草药, 2003, 34(8):736- 738.
[14]解方为,欧阳学农,蒋明德.红景天甙对人肝癌细胞的诱导分化作用[J],西南国防医药,2005,15 (6):613-615.
[15]解方为,欧阳学农,蒋明德.红景天甙对人肝癌细胞c-myc表达的逆转作用[J],西南国防医药,2006,16(2):130-131.
[16] Lei Liu, Hudgins WR, Shack S, et al. Cinnamic acid:A natural product with potential use in cancer intervention [J]. Int J Cancer, 1995, 629 (3):345- 350.
[17]钱海鑫刘俊卯.桂皮酸体外诱导人肝癌细胞分化[J],江苏医药杂志,2001,27(1):17-19.
[18]朱文渊,董济群,梁雪清.桂皮酸对HL-60细胞诱导分化[J].肿瘤防治研究, 2003, 30(2): 92-94.
[19]黄炜,黄济群,朱文渊,等.桂皮酸诱导白血病肝癌肺癌细胞的分化和抗肺癌细胞侵袭作用[J].中山医科大学学报,2002 ,23 (1) :40-43.
[20]葛林阜,董政军,姜国胜,等.淫羊藿甙对急性早幼粒白血病细胞端粒酶活性的影响[J].中国肿瘤生物治疗杂志,2002 ,9 (1) :36-38.
[21]葛林阜,董政军,姜国胜,等.淫羊藿甙对耐药与非耐药HL-60细胞增殖分化的作用[J].中华实用医学,2001 ,3 (18):9-11.
[22]张玲,王芸,毛海婷,等.淫羊藿甙抑制肿瘤细胞端粒酶活性及其调节机制的研究[J].中国免疫学杂志,2002 ,18 (3):191-196.
[23]王莎莉,王亚平,戴勤,等.当归多糖对人粒单系祖细胞和粒系白血病细胞株增殖分化的实验研究[J].重庆医科大学学报,2003,28(3):257-260.
[24]郑敏,王亚平.当归多糖对K562细胞增殖抑制与诱导分化的实验研究[J],中国中西医结合杂志,2002,22(1):54-57.
[25]梁永红,侯华新,黎丹戎,等.板蓝根二酮B体外抗癌活性研究[J],中草药,2000,31(7):531-533.
[26]侯华新,秦箐,黎丹戎,等.板蓝根高级不饱和脂肪组酸的体外抗人肝癌BEL-7402细胞活性[J],中国临床药学杂志,2002,11(1):16-19.
[27]李祺福,欧阳高亮,刘庆榕,等.中国鲎鲎素诱导人肝癌SMMC-7721细胞分化的观察[J],癌症,2002,21(5):480-483.